|
|
ÇöÀçÀ§Ä¡ : Ȩ > µµ¼¸ñ·Ï > Àüüµµ¼¸ñ·Ï > Åë°è |
Integrated Cardiac Safety: Assessment Methodologies for Noncardiac Drugs in Discovery, Development, and Postmarketing Surveillance |
|
|
ÁöÀºÀÌ |
: Turner |
¹ßÇàÀÏ |
: 2009 ³â |
ISBN |
: 9780470229644 |
Á¤Çà°¡ |
: 44,000 ¿ø |
ÆäÀÌÁö |
: 470 ÆäÀÌÁö |
ÆÇÇà¼ö |
: 1ÆÇ |
ÃâÆÇ»ç |
: Wiley |
|
|
|
|
ÀúÀÚ ¹× ¿ªÀÚ ¼Ò°³ |
|
|
|
Â÷·Ê |
PartA I: INTRODUCTION
1. The Importance of Cardiac Safety Assessments
2. The Biological Basis of Adverse Drug Reactions
PartA II: CARDIAC FUNCTION AND PATHOLOGY
3. Cardiac Structure and Function
4. Cardiac Pathophysiology and Disease
SECTION III: DRUG DISCOVERY AND NONCLINICAL DEVELOPMENT
5. Drug Discovery and Drug Design
6. Nonclinical Development
SECTION IV: PREAPPROVAL CLINICAL DEVELOPMENT
7. The Thorough QT/QTc Trial
8. General Safety Assessments
SECTION V: POSTMARKETING ASSESSMENT METHODOLOGIES
9. Therapeutic Use Trials and Meta-analyses
10. Assessment Methodologies in Nonexperimental Postmarketing Surveillance
11. Postmarketing Proarrythmic Cardiac Safety Assessments
12. Generalized Cardiac Safety
SECTION VI: BEHAVIORAL DRUG SAFETY
13. Medication Errors, Adherence, and Concordance
SECTION VII: INTEGRATIVE DISCUSSION
14. Future Directions in Drug Safety
|
|